Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aponermin plus CyBorD in newly diagnosed systemic light chain amyloidosis
ChiCTR2500102256Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aponermin, cyclophosphamide, bortezomib and dexamethasone in light-chain amyloidosis, sponsored by Tianjin Medical University General Hospital. Primary endpoint: Overall response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
aponermincyclophosphamidebortezomibdexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ChiCTR2500102256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102256.